Condition: Metastatic Breast Cancer · Sponsor: Institut Curie
A biopsy of a tumor lesion (breast or other localisation) will be performed for processing to establish avatars (patient-derived organoids -PDO). A personalized tumorogram for each patient will be provided, based on the results of the drug screening (= tumor predicted as sensitive, intermediate, resistant or non-evaluable for each drug tested). Patients with an informative tumorogram will receive one of the recommended treatments (line N+1) in the event of tumor progression, administered according to standard procedures and validated at medical meetings specific to each center, and their fate will be monitored.
This description comes directly from the study's public registry record.
Luc CABEL, MD · +33 1 56 24 55 00 · drci.promotion@curie.fr
Anne-Sophie Plissonnier · +33 1 47 11 23 78 · anne-sophie.plissonnier@curie.fr
Always discuss trial participation with your own doctor first.
| Institut Curie | Paris, France | Recruiting |
| Hôpital Saint-Louis - AP-HP Senopole | Paris, France | Not Yet Recruiting |
| Institut Curie | Saint-Cloud, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06459791